title: [Biotherapies for psoriasis: Options following the suspension of Raptiva?].
authors.forename: F
authors.initials: F
authors.lastname: Aubin
authors.forename: H
authors.initials: H
authors.lastname: Bachelez
authors.forename: J-C
authors.initials: JC
authors.lastname: Beani
authors.forename: P
authors.initials: P
authors.lastname: Berbis
authors.forename: M
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: V
authors.initials: V
authors.lastname: Descamps
authors.forename: L
authors.initials: L
authors.lastname: Dubertret
authors.forename: C
authors.initials: C
authors.lastname: Goujon
authors.forename: M
authors.initials: M
authors.lastname: Jeanmougin
authors.forename: M
authors.initials: M
authors.lastname: Le Maître
authors.forename: J-P
authors.initials: JP
authors.lastname: Ortonne
authors.forename: C
authors.initials: C
authors.lastname: Paul
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000627:therapeutic use; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; C472181:efalizumab